Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Praxis Precision Medicines (PRAX) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Praxis Precision Medicines (PRAX) over the last 4 years, with Q3 2025 value amounting to $22.0 million.

  • Praxis Precision Medicines' Shares Outstanding (Diluted Average) rose 1637.69% to $22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.0 million, marking a year-over-year increase of 1637.69%. This contributed to the annual value of $17.9 million for FY2024, which is 17154.89% up from last year.
  • Per Praxis Precision Medicines' latest filing, its Shares Outstanding (Diluted Average) stood at $22.0 million for Q3 2025, which was up 1637.69% from $21.5 million recorded in Q2 2025.
  • Praxis Precision Medicines' Shares Outstanding (Diluted Average)'s 5-year high stood at $45.8 million during Q3 2022, with a 5-year trough of $3.1 million in Q4 2022.
  • Its 4-year average for Shares Outstanding (Diluted Average) is $19.8 million, with a median of $18.8 million in 2024.
  • In the last 5 years, Praxis Precision Medicines' Shares Outstanding (Diluted Average) tumbled by 9221.17% in 2023 and then skyrocketed by 30488.23% in 2024.
  • Quarter analysis of 4 years shows Praxis Precision Medicines' Shares Outstanding (Diluted Average) stood at $3.1 million in 2022, then soared by 114.58% to $6.6 million in 2023, then soared by 171.55% to $17.9 million in 2024, then rose by 22.73% to $22.0 million in 2025.
  • Its last three reported values are $22.0 million in Q3 2025, $21.5 million for Q2 2025, and $21.1 million during Q1 2025.